Bagel, J., Armstrong, A. W., Warren, R. B., Papp, K. A., Thaçi, D., Menter, A., Cather, J., Augustin, M., Hippeli, L., Daamen, C., & Griffiths, C. E. (2023). Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial. SKIN The Journal of Cutaneous Medicine, 7(2), s117. https://doi.org/10.25251/skin.7.supp.117